Correction: Serwotka-Suszczak, A. M. et al. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. Int. J. Mol. Sci. 2017, 18, 401

Anna M Serwotka-Suszczak; Alicja M Sochaj-Gregorczyk; Jerzy Pieczykolan; Daniel Krowarsch; Filip Jelen; Jacek Otlewski

doi:10.3390/ijms19113676

Correction: Serwotka-Suszczak, A. M. et al. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. Int. J. Mol. Sci. 2017, 18, 401

Int J Mol Sci. 2018 Nov 20;19(11):3676. doi: 10.3390/ijms19113676.

Authors

Anna M Serwotka-Suszczak¹, Alicja M Sochaj-Gregorczyk², Jerzy Pieczykolan³, Daniel Krowarsch⁴, Filip Jelen⁵, Jacek Otlewski⁶

Affiliations

¹ Department of Protein Engineering, Faculty of Biotechnology, University of Wroclaw, 50-137 Wroclaw, Poland. aniaserwotka@wp.pl.
² Department of Protein Engineering, Faculty of Biotechnology, University of Wroclaw, 50-137 Wroclaw, Poland. alicja.sochaj-gregorczyk@uj.edu.pl.
³ Drug Discovery Department, Adamed Group, 05-152 Czosnow, Poland. jerzy.pieczykolan@celonpharma.com.
⁴ Department of Protein Biotechnology, Faculty of Biotechnology, University of Wroclaw, 50-137 Wroclaw, Poland. daniel.krowarsch@uwr.edu.pl.
⁵ Research and Development Department, Pure Biologics Ltd., 54-427 Wroclaw, Poland. filip@purebiologics.com.
⁶ Department of Protein Engineering, Faculty of Biotechnology, University of Wroclaw, 50-137 Wroclaw, Poland. jacek.otlewski@uwr.edu.pl.

Abstract

It has been brought to our attention that the affiliation of Dr. Jerzy Pieczykolan at the time when he was responsible for the work described in the paper [...].

Publication types

Published Erratum